Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism
NCT ID: NCT06545864
Last Updated: 2024-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
50 participants
OBSERVATIONAL
2024-10-01
2030-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Catheter Directed Interventions in Pulmonary Embolism
NCT03595085
Catheter-interventional Treatment of Pulmonary Embolism
NCT05456789
Safety and Efficacy of Thrombolysis in Combination With Endhole Aspiration in the Treatment of Acute DVT
NCT04297787
Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
NCT02604238
Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
NCT05172115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients who received systemic thrombolysis
patients have been diagnosed with acute intermediate-high pulmonary embolism received I.V. streptokinase if there are no contraindications.
Streptokinase Injection
250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
patients who underwent catheter-based intervention
patients have been diagnosed with acute intermediate-high pulmonary embolism underwent catheter-based intervention including thrombus aspiration or catheter directed thrombolysis using Penumbra System
Penumbra System
which comprised of several devices:
* RED Reperfusion Catheters
* Penumbra JET Reperfusion Catheters
* ACE Reperfusion Catheters
* MAX Reperfusion Catheters
* 3D Revascularization Device
* Penumbra ENGINE Aspiration Source
* Penumbra ENGINE Canister
* Aspiration Tubing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Streptokinase Injection
250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
Penumbra System
which comprised of several devices:
* RED Reperfusion Catheters
* Penumbra JET Reperfusion Catheters
* ACE Reperfusion Catheters
* MAX Reperfusion Catheters
* 3D Revascularization Device
* Penumbra ENGINE Aspiration Source
* Penumbra ENGINE Canister
* Aspiration Tubing
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Low risk, intermediate low risk, acute pulmonary embolism
* patients with RV masses will be excluded.
* Patient refusal of treatment strategy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mariam J William
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ayman K Mohamed, PHD
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Mohamed O Abdelhameed, master
Role: STUDY_DIRECTOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital University
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
123456@qerty
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.